These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9094145)

  • 1. Selegiline in ADHD adults: plasma monoamines and monoamine metabolites.
    Ernst M; Liebenauer LL; Tebeka D; Jons PH; Eisenhofer G; Murphy DL; Zametkin AJ
    Neuropsychopharmacology; 1997 Apr; 16(4):276-84. PubMed ID: 9094145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.
    Ernst M; Liebenauer LL; Jons PH; Tebeka D; Cohen RM; Zametkin AJ
    Psychopharmacol Bull; 1996; 32(3):327-34. PubMed ID: 8961775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder.
    Rubinstein S; Malone MA; Roberts W; Logan WJ
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):404-15. PubMed ID: 16958566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
    Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.
    Heinonen EH; Savijärvi M; Kotila M; Hajba A; Scheinin M
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):193-202. PubMed ID: 8369100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment.
    Zametkin A; Rapoport JL; Murphy DL; Linnoila M; Karoum F; Potter WZ; Ismond D
    Arch Gen Psychiatry; 1985 Oct; 42(10):969-73. PubMed ID: 2412521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential measures of 'sustained attention' in children with attention-deficit/hyperactivity or tic disorders: relations to monoamine metabolism.
    Oades RD
    Psychiatry Res; 2000 Mar; 93(2):165-78. PubMed ID: 10725533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    Laine K; Anttila M; Heinonen E; Helminen A; Huupponen R; Mäki-Ikola O; Reinikainen K; Scheinin M
    Clin Neuropharmacol; 1997 Oct; 20(5):419-33. PubMed ID: 9331518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
    J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural effects of monoamine reuptake inhibitors on symptomatic domains in an animal model of attention-deficit/hyperactivity disorder.
    Hiraide S; Ueno K; Yamaguchi T; Matsumoto M; Yanagawa Y; Yoshioka M; Togashi H
    Pharmacol Biochem Behav; 2013 Apr; 105():89-97. PubMed ID: 23380523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
    Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
    Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning.
    Wietecha L; Young J; Ruff D; Dunn D; Findling RL; Saylor K
    Clin Neuropharmacol; 2012; 35(3):125-33. PubMed ID: 22561876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.